title: [Fluorodeoxyglucose F18(FDG)-probe guided biopsy].
abstract: Although positron emission tomography-computed tomography (PET-CT) has improved the diagnosis of malignant and inflammatory abnormalities, histopathological examination is often required to supplement imaging examination in order to make a definite diagnosis. In some cases a lesion is not visible using conventional imaging techniques but is visible on a PET scan with fluorodeoxyglucose F18 (FDG). In other cases a lesion cannot be approached percutanuously because of localisation or size of the lesion. In these cases the surgeon can now perform an FDG-probe guided biopsy or resection. Using this technique the surgeon can peroperatively detect lesions that have taken up radioactive FDG - so-called FDG-avid lesions - and excise these for histopathological examination. This technique reduces the inadvertent excision of non-representative tissue and can be of value for localising FDG-avid lesions for total resections. FDG-probe guided surgery can potentially increase the sensitivity of diagnostic resections.
authors.affiliation: VU Medisch Centrum, Amsterdam, Afd. Chirurgie, the Netherlands. kjhartemink@hetnet.nl
authors.forename: Koen J
authors.initials: KJ
authors.lastname: Hartemink
authors.forename: Sandra
authors.initials: S
authors.lastname: Muller
authors.forename: Yvo M
authors.initials: YM
authors.lastname: Smulders
authors.forename: M
authors.initials: M
authors.lastname: Petrousjka van den Tol
authors.forename: Emile F I
authors.initials: EF
authors.lastname: Comans
mesh_terms: D001706:Biopsy / Q000295:instrumentation / Q000379:methods*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000000981:diagnostic imaging*; D009369:Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18